Symphogen A/S Announces Initiation of Phase 1/2 Trial of Sym004 in Patients with Advanced Solid Tumors in the US

COPENHAGEN & PRINCETON, N.J.--(BUSINESS WIRE)--Symphogen A/S today announced that it has initiated a Phase 1/2 human clinical trial in the US to evaluate the safety, tolerability and efficacy of its drug candidate Sym004 for the treatment of advanced solid tumors. Sym004 is composed of two anti-epidermal growth factor receptor (EGFR) monoclonal antibodies targeting different nonoverlapping EGFR epitopes.